Curanex Pharmaceuticals Inc. (CURX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Curanex Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing botanical drugs for inflammatory diseases. The company completed its Initial Public Offering (IPO) on August 27, 2025, and began trading on the Nasdaq Capital Market under the ticker "CURX." The company is currently in the preclinical development phase, with no commercial revenue.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(954,059) | $(91,166) | $(1,151,988) | $(215,567) |
| Operating Expenses | $951,327 | $93,295 | $1,146,437 | $217,696 |
| Cash and Equivalents (End of Period) | $5,830,537 | $244,317 | $5,830,537 | $244,317 |
| Total Assets | $14,478,157 | $517,935 | $14,478,157 | $517,935 |
| Total Liabilities | $185,955 | $14,575 | $185,955 | $14,575 |
| Shares Outstanding | 28,340,812 | 24,000,000 | 28,340,812 | 24,000,000 |
Material Changes vs. Prior Period
- Liquidity Surge: Cash balances increased from $148,891 at year-end 2024 to $5.83 million at September 30, 2025. This was driven by net proceeds of approximately $15.3 million from the IPO and the full exercise of the underwriters' over-allotment option.
- Expense Acceleration: Operating expenses increased significantly due to the initiation of FDA-mandated Investigational New Drug (IND)-enabling studies. Research & Development (R&D) expenses were $677,474 for Q3 2025 compared to $0 in Q3 2024.
- Prepaid Assets: Prepaid expenses rose to $8.59 million, primarily representing advance payments to Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) for ongoing studies.
- Debt Repayment: The company repaid $400,000 in principal plus $8,537 in interest on related-party shareholder loans in September 2025, resulting in zero outstanding related-party debt.
Outlook, Risks, and Management Commentary
- Going Concern: Management has alleviated substantial doubt regarding the company's ability to continue as a going concern due to the successful IPO and improved liquidity. The company believes current cash resources are sufficient for at least the next 12 months.
- Strategic Focus: Proceeds are being utilized for the development of the lead candidate, Phyto-N, specifically for ulcerative colitis, including GLP toxicology studies and IND application preparation.
- Nasdaq Compliance Risk: On November 5, 2025, the company received a notice from Nasdaq stating its closing bid price had been below $1.00 for 30 consecutive days. The company has a 180-day compliance period (until May 4, 2026) to regain compliance or risk delisting.
- Controls and Procedures: Management concluded that disclosure controls and procedures were not effective as of September 30, 2025.
- Patent Status: Four provisional patent applications acquired from a related party expired on March 18, 2025. The company filed an international PCT application on March 13, 2025, to maintain protection for three of the indications.
Investor Verification Checklist
- Nasdaq Compliance: Verify the company's progress in regaining the $1.00 minimum bid price to avoid delisting.
- Internal Controls: Review the specific material weaknesses identified in disclosure controls and the remediation plan.
- R&D Milestones: Monitor the timeline for the submission of the IND application for Phyto-N and the completion of GLP toxicology studies.
- Cash Burn Rate: Assess the sustainability of the $5.8 million cash balance against the high prepaid R&D spend and ongoing operating costs.
- Related Party Transactions: Confirm the terms of the asset purchase from Duraviva and the lease assignment to ensure fair value and independence.